Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine

Por Adema, Auke D, Floor, Karijn, Smid, Kees, Honeywell, Richard J, Scheffer, George L, Jansen, Gerrit, Peters, Godefridus J
Publicado no Springerplus (2014)

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

Por Adema, Auke D., Smid, Kees, Losekoot, Nienke, Honeywell, Richard J., Verheul, Henk M., Myhren, Finn, Sandvold, Marit L., Peters, Godefridus J.
Publicado em 2011

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

Por Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Poel, Dennis, Peters, Godefridus J., Griffioen, Arjan W., Verheul, Henk M. W.
Publicado no J Exp Clin Cancer Res (2016)

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells

Por Avan, Amir, Crea, Francesco, Paolicchi, Elisa, Funel, Niccola, Galvani, Elena, Marquez, Victor E, Honeywell, Richard J., Danesi, Romano, Peters, Godefridus J., Giovannetti, Elisa
Publicado em 2012

Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine

Por Bijnsdorp, Irene V., Schwendener, Reto A., Schott, Herbert, Fichtner, Iduna, Smid, Kees, Laan, Adrie C., Schott, Sarah, Losekoot, Nienke, Honeywell, Richard J., Peters, Godefridus J.
Publicado em 2009

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells

Por Martens-de Kemp, Sanne R., Dalm, Simone U., Wijnolts, Fiona M. J., Brink, Arjen, Honeywell, Richard J., Peters, Godefridus J., Braakhuis, Boudewijn J. M., Brakenhoff, Ruud H.
Publicado em 2013

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

Por Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Publicado no Cell Oncol (Dordr) (2015)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasc...

Por Gotink, Kristy J., Broxterman, Henk J., Honeywell, Richard J., Dekker, Henk, de Haas, Richard R., Miles, Kiersten M., Adelaiye, Remi, Griffioen, Arjan W., Peters, Godefridus J., Pili, Roberto, Verheul, Henk M.W.
Publicado no Oncoscience (2014)

A rapid homogeneous immunoassay to quantify gemcitabine in plasma for therapeutic drug monitoring (TDM)

Por Kozo, Daniel, Ross, Matt W., Jarrah, Justin, Barrett, Michael, Harney, Rebecca L., Courtney, Jodi B., Baburina, Irina, Holleran, Julianne L., Beumer, Jan H., Peters, Godefridus J., Honeywell, Richard J., Salamone, Salvatore J.
Publicado no Ther Drug Monit (2017)

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice

Por Timmers, Lonneke, Boons, Christel C. L. M., Mangnus, Dirk, Van de Ven, Peter M., Van den Berg, Pieter H., Beeker, Aart, Swart, Eleonora L., Honeywell, Richard J., Peters, Godefridus J., Boven, Epie, Hugtenburg, Jacqueline G.
Publicado no Front Pharmacol (2016)

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

Por Gotink, Kristy J., Broxterman, Henk J., Labots, Mariette, de Haas, Richard R., Dekker, Henk, Honeywell, Richard J., Rudek, Michelle A., Beerepoot, Laurens V., Musters, René J., Jansen, Gerrit, Griffioen, Arjan W., Assaraf, Yehuda G., Pili, Roberto, Peters, Godefridus J., Verheul, Henk M.W.
Publicado no Clin Cancer Res (2011)